Archival of Human Biological Samples in CU-Med Biobank

Sponsor

Chinese University of Hong Kong (Other)

Overall Status

Recruiting

CT.gov ID

NCT04706481

Collaborator

(none)

10,000

Enrollment

Location

371

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

CU-Med Biobank collaborates with different researchers for collecting and distributing human biospecimens and clinical data for assisting scientific research.

Condition or Disease	Intervention/Treatment	Phase
Healthy Cancer Heart Diseases Neurological Diseases or Conditions Kidney Diseases Diabetes Other Disease	Procedure: Specimen Collection

Detailed Description

CU-Med Biobank will collect and store high-quality specimens from cancer-related or other diseases. All samples are linked to annotated clinical data from approved consented protocols. This system provides researchers with high- quality biological samples and comprehensive clinical, pathological including molecular/genetic information for their research. This standardized CU-Med Biobank is a pivotal bridge to improve the translation of basic research into clinical applications. These findings will contribute to improve prevention, enhance diagnosis, develop new treatment and eventual cure of diseases.

Study Design

Study Type:

Observational [Patient Registry]

Anticipated Enrollment :

10000 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Archival of Human Biological Samples in CU-Med Biobank

Actual Study Start Date :

Jan 1, 2020

Anticipated Primary Completion Date :

Dec 1, 2050

Anticipated Study Completion Date :

Dec 1, 2050

Arms and Interventions

Arm	Intervention/Treatment
Healthy Control Healthy subjects who have provided consent for specimen collection	Procedure: Specimen Collection Specimens obtained from surgical, phlebotomy or other non-invasive procedure
Cancer or Other Diseases Diseased subjects who have provided consent for specimen collection	Procedure: Specimen Collection Specimens obtained from surgical, phlebotomy or other non-invasive procedure

Arm

Intervention/Treatment

Healthy Control

Healthy subjects who have provided consent for specimen collection

Procedure: Specimen Collection

Specimens obtained from surgical, phlebotomy or other non-invasive procedure

Cancer or Other Diseases

Diseased subjects who have provided consent for specimen collection

Procedure: Specimen Collection

Specimens obtained from surgical, phlebotomy or other non-invasive procedure

Outcome Measures

Primary Outcome Measures

To distribute human biospecimens for clinical research [99 years]
By using the biological samples from CU-Med Biobank, translational studies can be done.
To discover the pathological mechanism of different acute and chronic diseases such as cancer, stroke, heart disease, dementia & diabetes [99 years]
The relationship between different genome/proteome/bacteriome/virome and various diseases can be revealed, thus leading to a better prognostic and diagnostic outcome.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Enrolled subjects that have provided signed consent for the specimens and de-identified data to be collected, stored and distributed.

Exclusion Criteria:

Subjects without signed informed consent for the specimens and de-identified data to be collected, stored and distributed.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	CU-Med Biobank	Hong Kong		Hong Kong

Sponsors and Collaborators

Chinese University of Hong Kong

Investigators

Study Chair: Ching Wan MA, MB BChir, Chinese University of Hong Kong

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Webpage of CU-Med Biobank

Publications

None provided.

Responsible Party:

Professor Ronald C.W. Ma, Professor, Chinese University of Hong Kong

ClinicalTrials.gov Identifier:

NCT04706481

Other Study ID Numbers:

CREC 2019.152

First Posted:

Jan 12, 2021

Last Update Posted:

Mar 9, 2022

Last Verified:

Mar 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Professor Ronald C.W. Ma, Professor, Chinese University of Hong Kong

Biobanking

Additional relevant MeSH terms:

Nervous System Diseases

Kidney Diseases

Heart Diseases

Disease

Study Results

No Results Posted as of Mar 9, 2022